Groundbreaking new research on cystic fibrosis medication is being led by Irish experts.
Researchers at RCSI University of Medicine and Health Sciences are leading a new €3m study to investigate the real-world effects of the newest cystic fibrosis medications as they become available for people with CF.
The research will look at how a new triple combination cystic fibrosis drug, Kaftrio, will affect people in their day to day lives, rather than in controlled clinical trial conditions.
Kaftrio (known as TriKafta in the US) is a successor to Orkambi.
Professor Paul McNally from the RCSI said: “Our study will allow us to discover in detail how this powerful new treatment affects the health and everyday lives of people with cystic fibrosis, to understand why different people might respond differently to the drug and to gain insight into how this treatment might affect the very significant treatment burden that people with cystic fibrosis currently endure.
“Clinical trials occur under very controlled conditions and exclude many sick people with cystic fibrosis.
“‘Real-world’ studies are essential to confirm the trial findings and examine in-depth effects on the everyday lives of all people with cystic fibrosis.”
Philip Watt, CEO, Cystic Fibrosis Ireland added: “Cystic Fibrosis Ireland is proud to support this major research study that will provide much new detailed data on the impact of new and innovative CF medications across Europe and North America.”
